Why Is STRUCTURE THERAPEUTI ADR (GPCR) Stock Down Today?

GPCR stock fell 12.99% to $41.19 on September 8, 2026, amid mixed reactions to clinical trial data for its lead obesity drug candidates. The session move followed the release of topline results from the Phase 1/2a ACCG-2671 trial for aleniglipron, which showed 3.3% body weight loss but no evidence of plateauing in a longer-term open-label extension. While some analysts called the data encouraging, the stock’s sharp decline suggests investor skepticism about the drug’s long-term potential.

What Happened

Structure Therapeutics reported data from its ACCG-2671 trial, showing a ~6-day half-life for aleniglipron and no serious adverse events. The company also noted up to 3.3% body weight loss in the Phase 1/2a SAD trial. However, the ACCESS open-label extension showed 16.2% weight loss at 72 weeks, with no plateauing reported. Despite these results, the stock dropped sharply during the session. Jefferies raised its stock target on amylin data, while Clear Street described the obesity portfolio updates as encouraging. The SEC 8-K filing on the same day provided additional regulatory context.

What The Data Shows

GPCR opened at $47.25 and reached an intraday high of $49.00 before falling to a low of $40.94. The stock closed at $41.19, with 2.1 million shares traded, more than 2.8 times its 3-month average. The 52-week range is $18.49 to $94.90, and the stock printed 24 fresh 52-week lows on the day. The company has a market cap of $3.4 billion and an unprofitable track record, with a TTM EPS of -3.22.

What To Watch

Investors should monitor the company’s upcoming earnings date if one is scheduled. Otherwise, continued coverage from analysts and further trial updates will be key to assessing the stock’s trajectory.